Scholarlink

Objective <p>The prognostic value of cluster of differentiation 56 (CD56) in patients with multiple myeloma (MM) is controversial. This meta-analysis aimed to investigate the association of CD56 with overall survival (OS) and progression-free survival (PFS) in patients with MM.</p> Methods <p>Studies reporting the association of CD56 with survival outcomes in patients with MM were included. Hazard ratio (HR) values with 95% confidence intervals (CIs) were gathered for pooled analysis.</p> Results <p>Twenty-two studies with 2791 patients were included. CD56 negativity was associated with worse OS [HR (95% CI): 2.04 (1.57, 2.65), <i>p</i> &lt; 0.001] and PFS [HR (95% CI): 1.43 (1.23, 1.65), <i>p</i> &lt; 0.001] in patients with MM. Subgroup analyses stratified by regions and CD56 cutoff values were performed. CD56 negativity was associated with shorter OS in studies conducted in Asian countries, studies using ≤ 20% for the cutoff value, and studies using other cutoff values (all <i>p</i> &lt; 0.01). In studies conducted in regions other than Asia, CD56 was not associated with OS. Additionally, CD56 negativity was associated with worse PFS, regardless of region and CD56 cutoff value (all <i>p</i> &lt; 0.05). No publication bias was found, and the pooled analysis was robust.</p> Conclusion <p>CD56 negativity serves as a potential biomarker for predicting worse survival outcomes in patients with MM, especially in Asians, which could improve personalized treatment for these patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CD56 negativity is associated with worse survival outcomes in patients with multiple myeloma: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月23日

查看全文
  • Guiyang Zhu,
  • Shenchao Zhu,
  • Fei Yang,
  • Qin Tang

摘要

Objective

The prognostic value of cluster of differentiation 56 (CD56) in patients with multiple myeloma (MM) is controversial. This meta-analysis aimed to investigate the association of CD56 with overall survival (OS) and progression-free survival (PFS) in patients with MM.

Methods

Studies reporting the association of CD56 with survival outcomes in patients with MM were included. Hazard ratio (HR) values with 95% confidence intervals (CIs) were gathered for pooled analysis.

Results

Twenty-two studies with 2791 patients were included. CD56 negativity was associated with worse OS [HR (95% CI): 2.04 (1.57, 2.65), p < 0.001] and PFS [HR (95% CI): 1.43 (1.23, 1.65), p < 0.001] in patients with MM. Subgroup analyses stratified by regions and CD56 cutoff values were performed. CD56 negativity was associated with shorter OS in studies conducted in Asian countries, studies using ≤ 20% for the cutoff value, and studies using other cutoff values (all p < 0.01). In studies conducted in regions other than Asia, CD56 was not associated with OS. Additionally, CD56 negativity was associated with worse PFS, regardless of region and CD56 cutoff value (all p < 0.05). No publication bias was found, and the pooled analysis was robust.

Conclusion

CD56 negativity serves as a potential biomarker for predicting worse survival outcomes in patients with MM, especially in Asians, which could improve personalized treatment for these patients.